Pharmacokinetic and concentration-effect studies with intravenous metoclopramide.

  title={Pharmacokinetic and concentration-effect studies with intravenous metoclopramide.},
  author={D. Nicholas Bateman and Clare Kahn and Keith Mashiter and D S Davies},
  journal={British journal of clinical pharmacology},
  volume={6 5},
1 Pharmacokinetic and concentration-effect studies have been carried out following intravenous injection of 10 mg metoclopramide hydrochloride to seven normal male volunteers. 2 It is proposed that a two-compartment model adequately describes the disposition of the drug which is rapidly distributed (T1/2alpha = 4.9 +/- 1.1 min) and eliminated (T1/2beta = 165.7 +/- 20.2 min). Total body plasma clearance of the drug is high (10.9 +/- 1.5 ml min-1 kg-1) and approximates to liver plasma flow. 3… 

Figures and Tables from this paper

Single-dose pharmacokinetics of metoclopramide

Plasma concentration-time data following i.v. administration of metoclopramide suggest that the drug occurs at higher concentrations in tissues than in plasma, and that its clearance is probably limited by liver blood flow rather than liver metabolic capacity.

The pharmacokinetics of metoclopramide in man with observations in the dog.

In the dog the metabolic fate of metoclopramide is different to man with conjugation being a minor metabolic pathway and the half-life in the dog does not appear to be dose dependent.

Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography.

A rapid and sensitive method, based on liquid chromatography, was used to study disposition of metoclopramide in healthy volunteers following single doses intravenously and orally as aqueous solution and a slow release tablet to suggest a first-pass elimination of 25-40%.

Pharmacokinetics of metoclopramide in goats.

The pharmacokinetics of a parenteral formulation of metoclopramide (monochloride monohydrate) were determined following single intravenous and intramuscular 0.5-mg/kg doses to two groups of 4 goats in a crossover design by a two-compartment open model with first-order absorption.

Clinical Pharmacokinetics of Metoclopramide

  • D. Bateman
  • Medicine, Biology
    Clinical pharmacokinetics
  • 1983
Preliminary studies after ‘high dose’ metoclopramide demonstrate accumulation to high plasma concentrations with linear kinetics, suggesting that current high dose regimens are unnecessarily cumbersome.

Concentration effect studies with oral metoclopramide.

It has not been possible to define a concentration-effect relationship for the action of metoclopramide on the stomach and comparison with previous results after intravenous dosing suggests that the route of administration is of major importance in determining the action.

The pharmacokinetics of high dose metoclopramide in patients with neoplastic disease.

High dose metoclopramide infusions were administered to nineteen patients with bronchial carcinoma who were receiving intravenous cyclophosphamide as single agent chemotherapy and, with the exception of two patients, were completely effective in the prevention of nausea and vomiting.

Pharmacokinetics of High-Dose Metoclopramide in Cancer Patients

Despite considerable pharmacokinetic variability, intravenous administration of high doses of metoclopramide is relatively safe due to its large therapeutic index.

The pharmacokinetics of single doses of metoclopramide in renal failure

In comparison to previous studies on normal subjects these results indicate that clearance of metoclopramide in renal failure is approximately 30% of normals.

Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers.

The pharmacokinetics and pharmacodynamics of prochlorperazine were studied in healthy volunteers using a recently developed h.l.p.c. assay and the main adverse effect was akathisia which was reported by five out of eight subjects after the higher i.v. dose.



Pharmacokinetics and concentration‐effect relationships of intravenous and oral clonidine

Oral and intravenous clonidine induced significant falls in blood pressure and consistently caused marked sedation and dryness of the mouth and it is proposed that a two‐compartment model adequately describes the disposition of the drug.

The absorption and elimination of metoclopramide in three animal species

The findings in the rabbit and in the dog suggest that the liver plays an active role reducing the systemic availability of unchanged metoclopramide after oral administration, and first order elimination kinetics with short half‐lives and high apparent volumes of distribution were observed.

The dependence of paracetamol absorption on the rate of gastric emptying

There was a significant correlation between the rate of gastric emptying and the 0·4 and 0·24 h urinary excretion of paracetamol and its metabolites, and individual differences in the rates may contribute to variable absorption of many drugs.

Effects of intravenous and oral propantheline and metoclopramide on ethanol absorption

It is suggested that when propantheline is selected as an anticholinergic for clinical use, there is need for greater awareness of the marked reduction in bioavailability that results when the drug is administered at conventional therapeutic dosage by the oral as opposed to the intravenous route.

Proceedings: Is metoclopramide a directly acting dopamine receptor antagonist?

Evidence suggests that metoclopramide increases the synthesis and release of DA by analogy to the classical neuroleptic drugs, and these biochemical changes may be due to functional blockade of cerebral DA receptors suggested by the behavioural studies.

Letter: Metaclopramide and prolactin.

Phenobarbitone and metoclopramide show similar effects on xylose absorption both in vivo and in vitro but there is no such correlation with propantheline.

Studies of the effect of metoclopramide and apomorphine on gastric emptying and secretion in man

Apomorphine, in subnauseous doses (0·25 mg intravenously) slowed the gastric emptying of test meals containing sodium citrate, and 10 mg of intravenous metoclopramide abolished the slowing of gastrics emptying caused by apomorphine.

Metoclopramide stimulates prolactin secretion in man.

Serum prolactin concentrations increased approximately 6-fold after oral or intravenous administration of 10 mg of metoclopramide to adult men, which is consistent with the possibility that metoclobramide acts by inhibiting dopamine-mediated hypothalamic secretion of prolactIn inhibitory factor.


  • L. Ahtee
  • Biology, Chemistry
    British journal of pharmacology
  • 1975
It is suggested that metoclopramide produces catalepsy by blocking striatal dopamine receptors by blocking dopamine receptors in the central nervous system of rats.